Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Revenue: 2009-2024

Historic Revenue for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $614.4 million.

  • Ani Pharmaceuticals' Revenue rose 53.58% to $227.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $826.9 million, marking a year-over-year increase of 48.87%. This contributed to the annual value of $614.4 million for FY2024, which is 26.20% up from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Revenue is $614.4 million, which was up 26.20% from $486.8 million recorded in FY2023.
  • Ani Pharmaceuticals' Revenue's 5-year high stood at $614.4 million during FY2024, with a 5-year trough of $208.5 million in FY2020.
  • Over the past 3 years, Ani Pharmaceuticals' median Revenue value was $486.8 million (recorded in 2023), while the average stood at $472.5 million.
  • In the last 5 years, Ani Pharmaceuticals' Revenue decreased by 0.93% in 2020 and then skyrocketed by 53.87% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Revenue (MRY) stood at $208.5 million in 2020, then grew by 3.67% to $216.1 million in 2021, then skyrocketed by 46.38% to $316.4 million in 2022, then skyrocketed by 53.87% to $486.8 million in 2023, then grew by 26.20% to $614.4 million in 2024.
  • Its Revenue was $614.4 million in FY2024, compared to $486.8 million in FY2023 and $316.4 million in FY2022.